Core Viewpoint - Harbin Pharmaceutical Group Co., Ltd. (哈药股份) is undergoing a strategic transformation from marketing-driven growth to technology-driven innovation, focusing on high-tech generic drugs, innovative medicines, and traditional Chinese medicine [2][4]. Group 1: Innovation and Transformation - The company has significantly increased its R&D investment and is implementing a digital upgrade plan to enhance production efficiency and product quality [3][4]. - Harbin Pharmaceutical is establishing a new intelligent production system to align with modern pharmaceutical enterprise characteristics, aiming to become a benchmark for innovation in the national pharmaceutical industry [2][4]. Group 2: R&D System Reconstruction - The company has restructured its R&D system into a "one department and five institutes" model, focusing on various fields such as generic drugs, innovative drugs, and traditional Chinese medicine [5]. - Harbin Pharmaceutical is transitioning from a focus on generic drugs to a balanced emphasis on both innovative drugs and health products, with a clear strategic plan for R&D in key therapeutic areas [6][5]. Group 3: Marketing and Sales Innovation - The company is expanding its online sales through subsidiaries, leveraging a dual-track strategy to consolidate core product advantages and develop potential categories [7]. - Harbin Pharmaceutical is enhancing its marketing capabilities by integrating content e-commerce and traditional e-commerce, creating a synergistic marketing ecosystem for sustainable growth [7].